Skip to main content
. 2009 Sep;11(9):910–920. doi: 10.1593/neo.09618

Figure 7.

Figure 7

Survival fraction of KCI-18 cells treated with sunitinib and expression of VEGFR-2 and PDGFR-β sunitinib targets on cells and tumors. (A) Inhibition of cell growth in vitro. KCI-18 cells were treated with sunitinib doses of 0.1 to 5 µM and plated in a colony formation assay for 10 days. Bars represent the mean survival fraction ± SEM of triplicate wells. (B and C) Expression of VEGFR-2 and PDGFR-β on KCI-18 cells and tumors. KCI-18 cells or KTs were lysed, and protein extracts were first immunoprecipitated with anti-VEGFR-2 or anti-PDGFR-β Abs. Immune complexes were separated using protein A agarose beads, and the expression of VEGFR-2 and PDGFR-β was determined by Western blot analysis. (B) Expression of VEGFR-2 or anti-PDGFR-β on KCI-18 cells. (C) Expression of VEGFR-2 or PDGFR-β in KCI-18 KTs and NKs from mice treated with SU10, SU20, or SU40 compared with control (Con) mice.